D&D Pharmatech Q1 2026: Operating loss widens, but DD01 Ph2 success and pipeline progress
- Consolidated Q1 2026 revenue: KRW 129M (91% YoY decline, DD01 license fee), operating loss: KRW 11.12B (vs KRW 7.16B loss in Q1 2025), net loss: KRW 10.08B (vs KRW 9.86B loss)
- DD01 MASH Ph2: 75.8% achieved ≥30% liver fat reduction at 12 weeks (placebo 11.8%), primary endpoint met; 48-week results expected H1 2026
- Continued co-development with Pfizer (ex-Metsera) on oral obesity drugs; additional R&D service contract of KRW 1.83B signed in April 2026
- NLY01: Parkinson's Ph2 subgroup (<60y) efficacy confirmed; Alzheimer's Ph2 IND approved; MS IIT initiated May 2026
- TLY012: IND approved for chronic pancreatitis; CMO tech transfer ongoing; IND amendment to include liver fibrosis planned
- Issued KRW 226.5B CB in April 2026 (operating funds); signed R&D contract with Pfizer in April 2026
- Cash & cash equivalents: KRW 24.57B (from KRW 32.88B at end-2025); debt-to-equity ratio 25.1%; net debt negative
- R&D expenses: KRW 6.73B (5,223% of revenue); key licensing deals active (Pfizer, Salubris, Blue Earth)
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Quarterly Report (2026.03)
- Company: D&D Pharmatech (347850)
- Submission: D&D Pharmatech Inc.
- Receipt: 05-15-2026